CN113230385A - 一种缓解癌痛和缓解癌症的药物配方及使用方法 - Google Patents
一种缓解癌痛和缓解癌症的药物配方及使用方法 Download PDFInfo
- Publication number
- CN113230385A CN113230385A CN202110501624.1A CN202110501624A CN113230385A CN 113230385 A CN113230385 A CN 113230385A CN 202110501624 A CN202110501624 A CN 202110501624A CN 113230385 A CN113230385 A CN 113230385A
- Authority
- CN
- China
- Prior art keywords
- injection
- sodium chloride
- cancer
- chloride injection
- ivgtt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Animal Husbandry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种缓解癌痛和缓解癌症的药物配方及使用方法,涉及肿瘤医药技术领域。本发明提供的缓解癌痛和缓解癌症的药物配方,通过提供3个周期的用药配方,以缓解癌痛等肿瘤相关症状,并控制肿瘤发展。具有见效快(3天左右),缓解率高(肿瘤缩小的可能性在80%以上),缓解程度高的特点(肿瘤缩小的程度多在70%以上)。同时具有广谱性(适用于所有恶性肿瘤)、治疗疗效好,患者痛苦小的优势。
Description
技术领域
本发明涉及肿瘤医药技术领域,尤其涉及一种缓解癌痛和缓解癌症的药物配方及使用方法。
背景技术
深圳市保尔医疗服务有限公司的李宝平教授,经过三十余年的潜心研究和临床实践,探索出了一套安全有效的治疗癌症的药物配方,在实际临床应用中取得了显著疗效。
肿瘤是一个复杂的生态系统,除了肿瘤细胞本身以外,免疫细胞、间质细胞、血管以及神经都会在肿瘤处大量汇聚。因此,正常细胞转化为癌细胞是个生物学问题,癌细胞形成肿瘤是个生态学问题。解决细胞癌变这个问题,用生物学思路,解决癌细胞形成的肿瘤这个问题,应该用生态学思路。
李宝平教授经过三十多年的临床研究,认为肿瘤的问题可能是间质问题,并非癌细胞的问题。细胞一旦发生"癌变",由正常细胞转化来的癌细胞存在的唯一目的就是增殖,增殖是癌细胞的"使命“。细胞一旦癌变,就要完成10的13∽14次方的增殖使命。但是,癌细胞若只以细胞形式存在,是一个二维空间的存在。以细胞形式存在的癌细胞是不容于正常细胞社会的,犹如几个毛贼,会被正常细胞社会清除。癌细胞若想生存下去,必须改变存在方式,由二维存在转换为三维存在,而癌细胞的三维存在形式就是形成肿瘤,犹如啸聚山林。肿瘤是一个由癌细胞主动利用组织间质就地取材而构建的一个像城堡一样的结构,癌细胞在这个结构能够得以最大程度的存活。肿瘤间质的主要成分是成纤维细胞合成的胶原纤维。而成纤维细胞主要来源有(1)癌细胞从所在的正常组织中募集而来,(2)由癌细胞通过肿瘤细胞间质转化而来。
从显微镜下观察肿瘤的病理结构,癌细胞大多以聚集成团的巢性生长方式存在,其间被肿瘤间质分隔,像一个个的深宅大院。过多的间质导致肿瘤产生了一个最基本的物理属性--质地坚硬。肿瘤血管散布于肿瘤间质当中,与肿瘤细胞之间被间质分隔。通过血流进入肿瘤中的药物要经过肿瘤间质中的胶原纤维才能接触到癌细胞,间质中的胶原纤维成为了药物弥散的“屏障”。而且肿瘤细胞还可以改变肿瘤间质,营造出一个适宜癌细胞生存的间质微环境,使之成为利于癌细胞生存的"土壤"。因此,肿瘤间质被癌细胞构建成"屏障",改造成“土壤",癌细胞得以最大程度的存活,以完成其不断增殖的"使命"。因此,癌细胞越来越多,肿瘤越来越大并出现转移。肿瘤增大是癌细胞增殖的表现;转移是癌细胞增殖的手段。其目的就是完成10的13∽14次方的增殖使命。因此,也可以把肿瘤比做一个城堡,癌细胞比做是守军。治疗肿瘤就像是攻克城堡,而攻克城堡的关键在破城而不在杀敌。城破,守军会不战而降;城不破,守军会负隅顽抗。城破,守军非死既降;城不破,不可能对守军造成有效杀伤,不是打不死,而是打不着。肿瘤治疗亦如此。亦即,若能软坚(破除肿瘤间质),必能散结。坚软结散,坚不软,结不散。
发明内容
本发明所要解决的技术问题是如何使用现有药物形成新的配方,通过改变肿瘤间质结构,来缓解癌痛和缓解癌症。
需要说明的是,本发明提出的缓解癌症的药物配方是基于李宝平教授对癌细胞、癌瘤(病灶)、癌症三者间关系的研究。简而言之:
●肿瘤是个全身问题,不是个局部问题。
●癌细胞不等于癌瘤(病灶),癌瘤(病灶)不等于癌症。
●癌细胞是一种细胞形态,癌细胞不受调控,只增殖,不分化。癌细胞一旦形成,它就具有增殖使命感,它的增殖使命就是使其数量增加10的13∽14次方倍。癌细胞为了更好地完成其增殖使命而不被正常细胞消灭,就要构建癌瘤。
●癌瘤是癌细胞构建的,是由癌细胞及癌间质共同构成的一种类似于器官的一种三维立体组织结构,在这种组织结构当中,癌细胞受到癌间质的"庇护"和"供养",癌细胞在癌瘤中得以最大程度地存活,以保证其能完成其的增殖使命。由此,癌细胞只是具有增殖能力(相当于种子),而癌细胞增殖的快慢则取决于间质(相当于土壤)。因此,癌间质在决定着癌细胞的命运。
●由于癌细胞的增殖,癌瘤会增大及增多(转移)。因此,癌瘤增大是癌细胞增殖的表现,转移是增殖的手段。
●随着癌瘤的增大增多,必然会对宿主(病人)的身体产生影响,宿主的身体状态由健康态转为病态(出现症状),这个时侯称之为癌症。
综上所述,恶性肿瘤这个病在患者体内经历着三个阶段:正常细胞癌变成癌细胞→癌细胞构建成癌瘤→癌瘤影响到病人的健康。所以,癌瘤是癌细胞不断增殖的产物,癌症是癌瘤不断增大增多而引起的患者身体的变化。
由此我们可以知道,我们直接面对的是癌症,首先要解决的是病人的健康问题,其次才是癌瘤(病灶),再其次才是癌细胞。
所以,面对一个得了肿瘤的患者,我们首先要解决的问题是癌症。既然癌症是由癌瘤不断向前发展而造成的,因此我们治疗的首要任务就是控制发展。控制住发展,解决了癌症的问题,接着就要考虑如何解决癌灶的问题了。既然癌瘤中的间质决定了癌细胞的命运,改变癌灶中间质的结构(改变土壤),使其不能对癌细胞进行"庇护"和"供养",癌细胞必然会面临死亡的命运。
基于以上原理,我们提出的药物配方采用的总体策略是:
●扶正袪邪控制癌瘤发展。
●软坚散结改变癌瘤(病灶)结构。
为了解决上述问题,本发明提出以下技术方案:
一种缓解癌痛和缓解癌症的药物配方,其中,第一周期为以下药物配方:
醋酸奥曲肽注射液0.2mg;
注射用胸腺法新(日达仙)1.6mg;
0.9%氯化钠注射液100ml、康艾注射液10-20ml;
0.9%氯化钠注射液100ml、注射用香菇多糖1mg;
0.9%氯化钠注射液150-200ml、头孢哌酮钠舒巴坦钠(舒普深)3g;
0.9%氯化钠注射液200ml、脾多肽注射液4ml;
0.9%氯化钠注射液200ml、艾迪注射液40-50ml;
5%葡萄糖注射液200ml、消癌平注射液40ml;
0.9%氯化钠注射液100ml;
口服药:
甲磺酸阿帕替尼片(艾坦)0.125g;
吉非替尼片(伊瑞可)0.25g;
醋酸甲地孕酮分散片160mg;
盐酸二甲双胍片(格华止)0.5g;
艾瑞昔布片100mg;
银杏叶提取物片80mg;
水飞蓟素胶囊140mg;
第二周期新增以下药物配方:
新瑞白3mg;
0.9%氯化钠注射液100ml、还原性谷胱甘肽1.2g;
0.9%氯化钠注射液100ml、泮托拉唑钠40mg;
昂丹司琼注射液4mg;
0.9%氯化钠注射液100ml、注射用地西他滨10mg;
0.9%氯化钠注射液100ml、白介素-2 100万IU;
0.9%氯化钠注射液200ml、复方苦参注射液20ml;
第三周期停用地西他滨,更换为为以下药物配方:
0.9%氯化钠注射液100ml、注射用顺铂5-10mg;
0.9%氯化钠注射液100ml、氟尿嘧啶注射液0.25g;
新瑞白3mg。
进一步地,第一周期、第二周期、第三周期的时长均为5-7天(依患者情况有所调整)。
本发明还提供所述的缓解癌痛和缓解癌症的药物配方的使用方法,具体如下:
第一周期的药物配方使用方法:
醋酸奥曲肽注射液0.2mg,ih tid/Q6h;
注射用胸腺法新(日达仙)1.6mg,ih Biw(周二、周五);
0.9%氯化钠注射液100ml、康艾注射液10-20ml,ivgtt qd;
0.9%氯化钠注射液100ml、注射用香菇多糖1mg,ivgtt qd;
0.9%氯化钠注射液150-200ml、头孢哌酮钠舒巴坦钠(舒普深)3g,ivgtt qd/bid(应用5-7天);
0.9%氯化钠注射液200ml、脾多肽注射液4ml,ivgtt qd;
0.9%氯化钠注射液200ml、艾迪注射液40-50ml,ivgtt qd(应用5-7天);
5%葡萄糖注射液200ml、消癌平注射液40ml,ivgtt qd(应用5-7天);
0.9%氯化钠注射液100ml,冲管qd;
口服药:
第二周期新增的药物配方使用方法:
新瑞白3mg,ih st;
0.9%氯化钠注射液100ml、还原性谷胱甘肽1.2g,ivgtt qd;
0.9%氯化钠注射液100ml、泮托拉唑钠40mg,ivgtt qd;
昂丹司琼注射液4mg,静脉入壶qd;
0.9%氯化钠注射液100ml、注射用地西他滨10mg,ivgtt Q5d;
0.9%氯化钠注射液100ml、白介素-2 100万IU,ivgtt qd;
0.9%氯化钠注射液200ml、复方苦参注射液20ml,ivgtt qd;
第三周期停用注射用地西他滨后的替代药物配方使用方法:
0.9%氯化钠注射液100ml、注射用顺铂5-10mg,ivgtt Q9d(避光);
0.9%氯化钠注射液100ml、氟尿嘧啶注射液0.25g,ivgtt Q9d(避光);
新瑞白3mg,ih st。进一步地,第二周期的药物中,0.9%氯化钠注射液100ml配合使用注射用地西他滨10mg的输液时间≥3h。
进一步地,第三周期的药物中,0.9%氯化钠注射液100ml配合使用氟尿嘧啶注射液0.25g的输液时间≥8h。
与现有技术相比,本发明所能达到的技术效果包括:
本发明提供的缓解癌痛和缓解癌症的药物配方,通过提供3个周期的药物配方,以控制肿瘤发展,进而缩小肿瘤。具有见效快(3天左右),缓解率高(肿瘤缩小的可能性在80%以上)和缓解程度高的特点(肿瘤缩小的程度多在70%以上)。
具体实施方式
下面将对实施例中的技术方案进行清楚、完整地描述。显然,以下将描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
应当理解,当在本说明书和所附权利要求书中使用时,术语“包括”和“包含”指示所描述特征、整体、步骤、操作、元素和/或组件的存在,但并不排除一个或多个其它特征、整体、步骤、操作、元素、组件和/或其集合的存在或添加。
还应当理解,在此本发明实施例说明书中所使用的术语仅仅是出于描述特定实施例的目的而并不意在限制本发明实施例。如在本发明实施例说明书和所附权利要求书中所使用的那样,除非上下文清楚地指明其它情况,否则单数形式的“一”、“一个”及“该”意在包括复数形式。
实施例
本发明实施例提供一种缓解癌痛和缓解癌症的药物配方,包括三个周期的药物配方及相应的使用方法,其中,第一周期的药物配方和使用方法为:
醋酸奥曲肽注射液0.2mg,ih tid/Q6h;
注射用胸腺法新(日达仙)1.6mg,ih Biw(周二、周五);
0.9%氯化钠注射液100ml、康艾注射液10-20ml,ivgtt qd;
0.9%氯化钠注射液100ml、注射用香菇多糖1mg,ivgtt qd;
0.9%氯化钠注射液150-200ml、头孢哌酮钠舒巴坦钠(舒普深)3g,ivgtt qd/bid(应用5-7天);
0.9%氯化钠注射液200ml、脾多肽注射液4ml,ivgtt qd;
0.9%氯化钠注射液200ml、艾迪注射液40-50ml,ivgtt qd(应用5-7天);
5%葡萄糖注射液200ml、消癌平注射液40ml,ivgtt qd(应用5-7天);
0.9%氯化钠注射液100ml,冲管qd;
口服药:
第二周期新增的药物配方和使用方法:
新瑞白3mg,ih st;
0.9%氯化钠注射液100ml、还原性谷胱甘肽1.2g,ivgtt qd;
0.9%氯化钠注射液100ml、泮托拉唑钠40mg,ivgtt qd;
昂丹司琼注射液4mg,静脉入壶qd;
0.9%氯化钠注射液100ml、注射用地西他滨10mg,ivgtt Q5d;
0.9%氯化钠注射液100ml、白介素-2 100万IU,ivgtt qd;
0.9%氯化钠注射液200ml、复方苦参注射液20ml,ivgtt qd;
第三周期停用注射用地西他滨后的替代药物配方和使用方法:
0.9%氯化钠注射液100ml、注射用顺铂5-10mg,ivgtt Q9d(避光);
0.9%氯化钠注射液100ml、氟尿嘧啶注射液0.25g,ivgtt Q9d(避光);
新瑞白3mg,ih st。
在一实施例中,第二周期的药物中,0.9%氯化钠注射液100ml配合使用注射用地西他滨10mg的输液时间≥3h。
在一实施例中,第三周期的药物中,0.9%氯化钠注射液100ml配合使用氟尿嘧啶注射液0.25g的输液时间≥8h。
在一实施例中,第一周期、第二周期、第三周期的时长均为5-7天。
本发明的药物配方使用效果是先控制肿瘤的发展,减轻肿瘤症状,进而缩小肿瘤。具体临床表现为:
●控制发展阶段:5-7天。治疗思路为:
◆扶正祛邪:扶正为主,提高免疫调节因子的活力,采用胸腺肽α1(ⅰh)、香茹多糖(iv)和脾多肽(ⅳ)。祛邪为辅,使用康艾注射液、消癌平注射液、艾迪注射液或苦参注射液等。
◆减轻炎症等刺激肿瘤生长的因素,采用抗生素、塞来昔布、生长抑素等。
●缩小肿瘤阶段:约14天左右。治疗思路为:
◆软坚,使用TKI类药物如易瑞沙、伊瑞可。
◆散结、活血化瘀,使肿瘤血管正常化,采用甲磺酸阿帕替尼)。
◆扶正祛邪,并加大祛邪力度,采用低剂量顺铂+5Fu,连用14天左右。或低剂量地西他滨5天+低剂量顺铂和5Fu9天左右。
本发明提供的缓解癌痛和缓解癌症的药物配方,其临床优势如下:
●安全性好。此药物配方与细胞毒治疗(放疗、化疗)不同,属于非细胞毒治疗。对病人身体没有大的伤害,多年临床实践未发现严重治疗并发症。
●起效快。平均治疗3天左右,患者的相关症状就会改善或明显改善。
●有效率高。经20天左右治疗,80%左右的患者癌瘤病灶会缩小,缩小程度多在70%以上。
●可与其他治疗技术相结合。如与热疗、冷冻、免疫治疗等技术相结合,可以起到1+1>2的治疗效果;
●是目前唯一一个不用止痛药而能有效缓解癌痛的临床手段,有效率在90%以上。
采用本发明提供的缓解癌痛和缓解癌症的药物配方,缓解癌痛的综合临床结果为:
●治疗一天,疼痛减轻。
●治疗三天,疼痛明显减轻。
●治疗7天,疼痛基本消失。
●有效率大于90%。
采用本发明提供的缓解癌痛和缓解癌症的药物配方,改变癌灶的综合临床结果:
●治疗一周,疼痛明显减轻。
●治疗两周,疼痛基本消失,病灶变化。
●治疗三周,病灶进一步变化。
●病灶的变化包括:病灶密度减低,病灶形态坍缩,病灶体积变小等。
在上述实施例中,对各个实施例的描述都各有侧重,某个实施例中没有详细描述的部分,可以参见其他实施例的相关描述。
以上所述,为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到各种等效的修改或替换,这些修改或替换都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以权利要求的保护范围为准。
Claims (5)
1.一种缓解癌痛和缓解癌症的药物配方,其特征在于,第一周期为以下药物配方:
醋酸奥曲肽注射液0.2mg;
注射用胸腺法新1.6mg;
0.9%氯化钠注射液100ml、康艾注射液10-20ml;
0.9%氯化钠注射液100ml、注射用香菇多糖1mg;
0.9%氯化钠注射液150-200ml、头孢哌酮钠舒巴坦钠3g;
0.9%氯化钠注射液200ml、脾多肽注射液4ml;
0.9%氯化钠注射液200ml、艾迪注射液40-50ml;
5%葡萄糖注射液200ml、消癌平注射液40ml;
0.9%氯化钠注射液100ml;
口服药:
甲磺酸阿帕替尼片0.125g;
吉非替尼片0.25g;
醋酸甲地孕酮分散片160mg;
盐酸二甲双胍片0.5g;
艾瑞昔布片100mg;
银杏叶提取物片80mg;
水飞蓟素胶囊140mg;
第二周期新增以下药物配方:
新瑞白3mg;
0.9%氯化钠注射液100ml、还原性谷胱甘肽1.2g;
0.9%氯化钠注射液100ml、泮托拉唑钠40mg;
昂丹司琼注射液4mg;
0.9%氯化钠注射液100ml、注射用地西他滨10mg;
0.9%氯化钠注射液100ml、白介素-2 100万IU;
0.9%氯化钠注射液200ml、复方苦参注射液20ml;
第三周期停用地西他滨,更换为以下药物配方:
0.9%氯化钠注射液100ml、注射用顺铂5-10mg;
0.9%氯化钠注射液100ml、氟尿嘧啶注射液0.25g;
新瑞白3mg。
2.如权利要求1所述的缓解癌痛和缓解癌症的药物配方,其特征在于,第一周期、第二周期、第三周期的时长均为5-7天。
3.如权利要求1或2所述的缓解癌痛和缓解癌症的药物配方的使用方法,其特征在于,具体如下:
第一周期的药物配方使用方法:
醋酸奥曲肽注射液0.2mg,ih tid/Q6h;
注射用胸腺法新1.6mg,ih Biw;
0.9%氯化钠注射液100ml、康艾注射液10-20ml,ivgtt qd;
0.9%氯化钠注射液100ml、注射用香菇多糖1mg,ivgtt qd;
0.9%氯化钠注射液150-200ml、头孢哌酮钠舒巴坦钠3g,ivgtt qd/bid;
0.9%氯化钠注射液200ml、脾多肽注射液4ml,ivgtt qd;
0.9%氯化钠注射液200ml、艾迪注射液40-50ml,ivgtt qd;
5%葡萄糖注射液200ml、消癌平注射液40ml,ivgtt qd;
0.9%氯化钠注射液100ml,冲管qd;
口服药:
第二周期新增的药物配方使用方法:
新瑞白3mg,ih st;
0.9%氯化钠注射液100ml、还原性谷胱甘肽1.2g,ivgtt qd;
0.9%氯化钠注射液100ml、泮托拉唑钠40mg,ivgtt qd;
昂丹司琼注射液4mg,静脉入壶qd;
0.9%氯化钠注射液100ml、注射用地西他滨10mg,ivgtt Q5d;
0.9%氯化钠注射液100ml、白介素-2 100万IU,ivgtt qd;
0.9%氯化钠注射液200ml、复方苦参注射液20ml,ivgtt qd;
第三周期停用注射用地西他滨后的替代药物配方使用方法:
0.9%氯化钠注射液100ml、注射用顺铂5-10mg,ivgtt Q9d;
0.9%氯化钠注射液100ml、氟尿嘧啶注射液0.25g,ivgtt Q9d;
新瑞白3mg,ih st。
4.如权利要求3所述的缓解癌痛和缓解癌症的药物配方的使用方法,其特征在于,第二周期的药物中,0.9%氯化钠注射液100ml配合注射用地西他滨10mg的输液时间≥3h。
5.如权利要求3所述的缓解癌痛和缓解癌症的药物配方的使用方法,其特征在于,第三周期的药物中,0.9%氯化钠注射液100ml配合氟尿嘧啶注射液0.25g的输液时间≥8h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110501624.1A CN113230385A (zh) | 2021-05-08 | 2021-05-08 | 一种缓解癌痛和缓解癌症的药物配方及使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110501624.1A CN113230385A (zh) | 2021-05-08 | 2021-05-08 | 一种缓解癌痛和缓解癌症的药物配方及使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113230385A true CN113230385A (zh) | 2021-08-10 |
Family
ID=77132776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110501624.1A Pending CN113230385A (zh) | 2021-05-08 | 2021-05-08 | 一种缓解癌痛和缓解癌症的药物配方及使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113230385A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1187773A (zh) * | 1995-04-18 | 1998-07-15 | 印纳药品股份有限公司 | 治疗疼痛的方法 |
CN101804197A (zh) * | 2010-05-21 | 2010-08-18 | 魏华 | 一种用于癌症骨转移的药物组合物及其用途 |
CN102188457A (zh) * | 2011-06-03 | 2011-09-21 | 杨林军 | 癌症的科学治疗方法及广谱癌症治愈药物 |
CA2993659A1 (en) * | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
JP2017533947A (ja) * | 2014-11-14 | 2017-11-16 | ドラッグ デリバリー インターナショナル リミテッド | 医薬の加工 |
CN107831243A (zh) * | 2017-12-19 | 2018-03-23 | 广西壮族自治区梧州食品药品检验所 | Hplc—elsd测定康艾注射液中黄芪甲苷含量的方法 |
-
2021
- 2021-05-08 CN CN202110501624.1A patent/CN113230385A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1187773A (zh) * | 1995-04-18 | 1998-07-15 | 印纳药品股份有限公司 | 治疗疼痛的方法 |
CN101804197A (zh) * | 2010-05-21 | 2010-08-18 | 魏华 | 一种用于癌症骨转移的药物组合物及其用途 |
CN102188457A (zh) * | 2011-06-03 | 2011-09-21 | 杨林军 | 癌症的科学治疗方法及广谱癌症治愈药物 |
JP2017533947A (ja) * | 2014-11-14 | 2017-11-16 | ドラッグ デリバリー インターナショナル リミテッド | 医薬の加工 |
US20180055773A1 (en) * | 2014-11-14 | 2018-03-01 | Drug Delivery International Ltd. | Pharmaceutical processing |
CA2993659A1 (en) * | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
CN107831243A (zh) * | 2017-12-19 | 2018-03-23 | 广西壮族自治区梧州食品药品检验所 | Hplc—elsd测定康艾注射液中黄芪甲苷含量的方法 |
Non-Patent Citations (2)
Title |
---|
朱霞;: "乳腺癌根治术后应用多西紫杉醇联合卡培他滨化疗及心理干预的临床观察", 药品评价, no. 07, pages 58 - 60 * |
毛瑞芬等: "口服吗啡缓释片与静脉自控镇痛对晚期癌性疼痛的临床", 《临床荟萃》, vol. 21, no. 17, pages 1267 - 1268 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101612400A (zh) | 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用 | |
CN105213394A (zh) | 具有抗肿瘤活性的喹啉衍生物 | |
CN113230385A (zh) | 一种缓解癌痛和缓解癌症的药物配方及使用方法 | |
CN101085184A (zh) | 一种治疗乳腺癌的中药 | |
CN101342175A (zh) | 西地那非在制备抗肿瘤药物中的应用 | |
CN104000804A (zh) | 普罗布考及其衍生物抗肿瘤转移的用途 | |
CN102225067B (zh) | 一种治疗胃癌的药物组合物 | |
CN1316972C (zh) | 一种抗癌止痛制剂 | |
CN113209149A (zh) | 米托蒽醌与人参总皂苷联合用药在制备治疗胃癌药物中的应用 | |
CN111494385A (zh) | 一种治疗卵巢癌的药物及其制备方法和用途 | |
CN101829193B (zh) | 一种治疗宫颈糜烂的药物组合物及其制备方法 | |
CN109010495A (zh) | 一种中药组合物及其制备方法和应用 | |
CN108635560A (zh) | 一种治疗淋巴瘤的中药及其制备方法 | |
Wu et al. | Review and prospect: prevention and treatment of lung related malignant tumors by tonifying qi and resolving phlegm method | |
CN101829253B (zh) | 一种治疗宫颈糜烂的药物组合物及其制备方法 | |
CN102846668A (zh) | 一种纳米美洲大蠊的制备方法 | |
US11684631B2 (en) | Method of treating cancer with composition of traditional Chinese medicine and its preparation method thereof | |
CN101829167B (zh) | 一种治疗宫颈糜烂的药物组合物及其制备方法 | |
HIGGINS | Chemotherapy, adjuvant to surgery, for gastrointestinal cancer | |
CN101856359A (zh) | 一种抗急性髓系白血病的药物组合物 | |
CN101991841A (zh) | 一种治疗癌症的药物组合物及其制备方法 | |
CN116492423A (zh) | 一种用于预防和治疗肺癌的中药组合物 | |
CN103316299B (zh) | 一种治疗原发性肝癌的中药组合物 | |
CN106668061B (zh) | 一种含有顺铂的抗癌药物组合物 | |
CN118252883A (zh) | 一种治疗卵巢癌的中药组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |